- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Posterior Urethral Cancer in Japan
Total 1146 results
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Pancreatic CancerJapan
-
Loxo Oncology, Inc.Eli Lilly and CompanyAvailableBreast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET AlterationSpain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
-
Merck Sharp & Dohme LLCCompleted
-
Taiho Oncology, Inc.RecruitingNon-Small Cell Lung CancerUnited States, France, Italy, Korea, Republic of, Japan, Germany, Spain, Netherlands, United Kingdom
-
Hoffmann-La RocheTerminatedBreast CancerUnited States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
-
AmgenActive, not recruitingNeuroendocrine Prostate CancerBelgium, United States, Austria, Spain, Australia, Netherlands, France, United Kingdom, Japan
-
AbbVieTerminatedCancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)United States, France, Israel, Japan, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
SanofiActive, not recruitingAdenocarcinoma Gastric | Gastrooesophageal CancerJapan, Belgium, Korea, Republic of, Spain, Russian Federation, Turkey
-
Novartis PharmaceuticalsTerminatedIn Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung CancerUnited States, Italy, Taiwan, Belgium, Spain, Germany, Japan
-
AmgenCompletedSquamous-Cell Non-Small-Cell Lung CancerFrance, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
-
AmgenRecruitingGastric Cancer | Gastroesophageal Junction CancerJapan, Korea, Republic of, Taiwan, Singapore, United States
-
AbbVieActive, not recruitingAdvanced Solid Tumors CancerUnited States, Belgium, France, Italy, Japan, Korea, Republic of, Netherlands, Taiwan, Finland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCervical CancerUnited States, Spain, Japan
-
Novartis PharmaceuticalsTerminatedMelanoma | Ovarian Cancer | NSCLC | Other Solid TumorsItaly, Spain, Netherlands, France, Korea, Republic of, Switzerland, Germany, Japan, United States, Canada
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico, Korea, Republic of, Taiwan
-
Orient Europharma Co., Ltd.NanoCarrier Co., Ltd.CompletedPancreatic NeoplasmsTaiwan, Japan, Hong Kong, Singapore, Philippines, Malaysia, Korea, Republic of
-
National Cancer Institute, NaplesRecruitingEndometrial CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, United Kingdom
-
Hoffmann-La RocheRecruitingSmall Cell Lung Cancer | Neuroendocrine CarcinomaUnited States, Japan, Denmark, Spain, Poland
-
Taiho Oncology, Inc.CompletedBreast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR TumorsFrance, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
-
Novartis PharmaceuticalsTerminatedAdvanced Non Small Cell Lung Cancer (NSCLC)France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
-
Daiichi SankyoAstraZenecaActive, not recruitingAdvanced Colorectal CancerKorea, Republic of, United States, Taiwan, Belgium, Spain, Japan, United Kingdom, France, Italy, Australia
-
AbbVieCompletedCancer | Advanced Solid Tumors | Hematologic MalignanciesUnited States, Japan, Netherlands, Spain
-
AstraZenecaRecruiting
-
Novartis PharmaceuticalsTerminatedNon-small Cell Lung Cancer (NSCLC)Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
-
SanofiCompleted
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands, Italy
-
SanofiActive, not recruitingNon-squamous Non-small Cell Lung CancerBelgium, Italy, Spain, Japan, United States, France, Turkey
-
AbbVieActive, not recruitingNon Small Cell Lung CancerUnited States, Australia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Taiwan
-
AstraZenecaRecruitingBiliary Tract CancerJapan
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdCompletedVarious Advanced CancerUnited States, Belgium, France, Germany, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
-
PfizerCompletedNon-small Cell Lung Cancer With EGFR-Activating MutationsItaly, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
-
Australasian Gastro-Intestinal Trials GroupBristol-Myers Squibb; Bayer; Syneos Health; University of Sydney; National Cancer... and other collaboratorsActive, not recruitingGastro-Oesophageal CancerKorea, Republic of, Australia, Taiwan, United States, Germany, Japan, Spain, Italy, Austria
-
PfizerActive, not recruitingBreast Cancer | Small Cell Lung Cancer | Ovarian CancerUnited States, China, Japan, Mexico, Bulgaria, Argentina
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedCancerUnited States, United Kingdom, Japan, Norway, Spain, Taiwan, France, Germany, Korea, Republic of, Italy, Netherlands
-
Hoffmann-La RocheCompletedTriple-negative Breast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
-
AstraZenecaDaiichi SankyoRecruitingGastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate CancerSpain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
-
Astellas Pharma Global Development, Inc.RecruitingGastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)United States, Japan, Italy, Korea, Republic of, Taiwan, France
-
Chugai PharmaceuticalJapan Lung Cancer SocietyCompletedNon-small Cell Lung Cancer | Extensive Disease Small Cell Lung CancerJapan
-
Eisai Inc.Bliss Biopharmaceutical (Hangzhou) Co., LtdRecruiting
-
Japan Adjuvant Study Group of Pancreatic CancerJapan Agency for Medical Research and Development; Pharma Valley CenterCompletedPancreatic CancerJapan
-
ASLAN PharmaceuticalsSyneos Health; bioRASI, LLC; CMIC Co, Ltd. JapanCompletedBiliary Tract CancerUnited States, Australia, China, Hong Kong, Hungary, Japan, Korea, Republic of, Poland, Singapore, Spain, Taiwan
-
TakedaCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerJapan
-
AmgenCompletedProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCholangiocarcinoma | Biliary Tract Cancer | Gallbladder CancerKorea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
AstraZenecaRecruitingCarcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction CancerUnited States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia